cbIC型甲基丙二酸血症基因型与临床表型及疗效的关系

宇亚芬; 黎芳; 麻宏伟

doi:10.7499/j.issn.1008-8830.2015.08.002

PDF(1363 KB)

HTML

中国当代儿科杂志 ›› 2015, Vol. 17 ›› Issue (8) : 769-774. DOI: 10.7499/j.issn.1008-8830.2015.08.002

论著·临床研究

cbIC型甲基丙二酸血症基因型与临床表型及疗效的关系

宇亚芬, 黎芳, 麻宏伟

作者信息 +

Relationship of genotypes with clinical phenotypes and outcomes in children with cobalamin C type combined methylmalonic aciduria and homocystinuria

YU Ya-Fen, LI Fang, MA Hong-Wei

Author information +

文章历史 +

摘要

目的分析cbIC型甲基丙二酸血症伴同型半胱氨酸血症(合并型MMA)基因突变情况、临床特点及治疗转归,探讨基因型与临床表型及疗效之间的关系。方法回顾性分析16例经基因检测确诊为cbIC型MMA患儿的临床资料。按发病年龄分为早发型(≤1岁)及晚发型(> 1岁)。按临床表型分为轻型、中间型及重型。治疗方法为肌肉注射维生素B12(氰钴胺)/羟钴胺、口服甜菜碱、叶酸及左旋肉碱等。结果早发型15例(重型11例、中间型4例),晚发型(轻型)1例。发现7种已经报道的突变及2种新发突变(c.445_446delTG和c.349G> C)。c.609G> A及c.658_660delAAG为最常见的突变(13/16,81%),二者导致的复合杂合突变为最常见(4/16,25%)的基因型,患者小头畸形及眼部问题表现突出且治疗后无缓解。晚发型这例患儿治疗后临床表型正常,早发型15例患儿表型越重、疗效越差。结论我国cblC型MMA以早发型为主,存在热点突变c.609G > A和c.658_660delAAG;患儿临床表型与疗效相关。

Abstract

Objective To analyze mutation types, clinical features, and treatment outcomes of cobalamin C (cblC) type combined methylmalonic aciduria and homocystinuria (MMA-HC) and to investigate the relationship of genotypes with clinical phenotypes and outcomes. Methods The clinical data of 16 Chinese children diagnosed with cblC type MMA-HC by gene analysis were retrospectively analyzed. According to the onset age, the patients were classified into early onset (≤1 year) and late onset (> 1 year). According to the clinical phenotype, the patients were classified into mild, moderate, and severe groups. All the patients were treated with vitamin B12 (cyanocobalamin) or hydroxocobalamin, betaine, folate, vitamin B6, and L-carnitine. Results Fifteen patients belonged to the early onset type, including 11 in the severe group and 4 in the moderate group. The remaining one belonged to the late onset type. Seven reported mutations and two novel mutations (c.445_446delTG and c.349G> c) were detected. The c.609G> A and c.658_660delAAG were the most common mutations detected in 13 (81%) out of 16 patients. The genotype caused by compound heterozygous mutations of these two alleles (c.609 G> A/c.658_660delAAG) was the most common in the patients, detected in 4 (25%) out of 16 patients. Patients with this genotype had severe microcephaly and eye diseases and these clinical manifestations were not improved after the treatment. The patient with late-onset cblC type MMA-HC had normal clinical phenotypes after treatment. In the 15 early onset patients, the more severe the clinical phenotype, the worse the treatment outcome. Conclusions The cblC type MMA-HC mainly manifests as early onset in China and c.609G > A and c.658_660delAAG are the most common mutations causing this disease. The clinical phenotypes are associated with the outcomes in children with cblC type MMA-HC.

导出引用

宇亚芬, 黎芳, 麻宏伟. cbIC型甲基丙二酸血症基因型与临床表型及疗效的关系[J]. 中国当代儿科杂志. 2015, 17(8): 769-774 https://doi.org/10.7499/j.issn.1008-8830.2015.08.002

YU Ya-Fen, LI Fang, MA Hong-Wei. Relationship of genotypes with clinical phenotypes and outcomes in children with cobalamin C type combined methylmalonic aciduria and homocystinuria[J]. Chinese Journal of Contemporary Pediatrics. 2015, 17(8): 769-774 https://doi.org/10.7499/j.issn.1008-8830.2015.08.002

参考文献

[1] Fowler B, Leonard JV, Baumgartner MR. Causes of and diagnostic approach to methylmalonic acidurias[J]. J Inherit Metab Dis, 2008, 31(3): 350-360.
[2] Liu MY, Yang YL, Chang YC, et al. Mutation spectrum of MMACHC in Chinese patients with combined methylmalonic aciduria and homocystinuria[J]. J Hum Genet, 2010, 55(9): 621-626.
[3] 毋盛楠, 韩连书, 叶军, 等. 甲基丙二酸血症患者血串联质谱及尿气相色谱质谱检测分析[J]. 中华医学杂志, 2013, 93(8): 561-565.
[4] Lerner-Ellis JP, Tirone JC, Pawelek PD, et al. Identification of the gene responsible for methylmalonic aciduria and homocystinuria, cblC type[J]. Nat Genet, 2006, 38(1): 93-100.
[5] Fischer S, Huemer M, Baumgartner M, et al. Clinical presentation and outcome in a series of 88 patients with the cblC defect[J]. J Inherit Metab Dis, 2014, 37(5): 831-840.
[6] 张尧, 宋金青, 刘平, 等. 甲基丙二酸尿症伴同型半胱氨酸血症57例临床分析[J]. 中华儿科杂志, 2007, 45(7): 513-517.
[7] Wang F, Han LH, Yang YL, et al. Clinical, biochemical, and molecular analysis of combined methylmalonic acidemia and hyperhomocysteinemia (cblC type) in China[J]. J Inherit Metab Dis, 2010, 33 (Suppl 3): S435-S442.
[8] 刘玉鹏, 马艳艳, 吴桐, 等. 早发型甲基丙二酸尿症160例新生儿期异常表现[J]. 中华儿科杂志, 2012, 50(6): 410-414.
[9] 王斐, 韩连书, 胡宇慧, 等. 甲基丙二酸血症伴同型半胱氨酸血症患儿基因突变分析[J]. 中华儿科杂志, 2009, 47(3), 189-193.
[10] 韩连书, 王斐, 胡宇慧, 等. 甲基丙二酸血症伴同型半胱氨酸血症患儿临床及基因突变分析[J]. 中华内分泌杂志, 2009, 25(8): 405-407.
[11] Morel CF, Lerner-Ellis JP, Rosenblatt DS, et al. Combined methylm alonic aciduria and homocystinuria (cblC): phenotype-genotype correla tions and ethnic-specific observations[J]. Mol Genet Metab, 2006, 88(4): 315-321.
[12] Fischer S, Huemer M, Baumgartner M, et al. Clinical presentation and outcome in a series of 88 patients with the cblC defect[J]. J Inherit Metab Dis, 2014, 37(5): 831-840.
[13] Martina Huemer, Sabine Scholl-Bürgi, et al. Three new cases of late-onset cblC defect and review of the literature illustrating when to consider inborn errors of metabolism beyond infancy[J]. Orphanet J Rare Diseases, 2014, 9: 161.
[14] Debray FG, Boulanger Y, Khiat A, et al. Reduced brain choline in homocystinuria due to remethylation defects[J]. Neurology, 2008, 71(1): 44-49.
[15] 刘黎黎, 侯新琳, 周丛乐, 等. 以脑积水起病的甲基丙二酸尿症合并同型半胱氨酸血症1例报道[J]. 中国当代儿科杂志, 2013, 15(4): 313-315.
[16] Bodamer OA, Sahoo T, Beaudet AL, et al. Creatine metabolism in combined methylmalonic aciduria and homocystinuria[J]. Ann Neurol, 2005, 57(4): 557-560.
[17] Roehrs C, Garrido-Sanabria ER, Silive AC, et a1. Succinate in creases neuronal post-synaptic excitatory potentials in vitro an d induces convulsive behavior through N-methyl-D-aspartated mediated mechanism[J].Neuroscience, 2004, 125(4): 965-971.
[18] Malfatti CR, Perry ML, Schweigert D, et al. Convulsions in-duced by methylmalonic acid are associated with glutamic acid deearboxylase inhibition in rats: a role for GABA in the seizuyes presented by methylmalonic acidemic patients?[J]. Neuroscience, 2007, 146(4): 1879-1887.
[19] Martinelli D, Deodato F, Dionisi-Vici C. Cobalamin C defect: natural history, pathophysiology, and treatment[J]. J Inherit Metab Dis, 2011, 34(1): 127-135.
[20] Froese DS, Zhang J, Healy S, et al. Mechanism of vitamin B12-responsiveness in cblC methylmalonic aciduria with homocystinuria[J]. Mol Genet Metab, 2009, 98(4): 338-343.
[21] Matos IV, Castejón E, Meavilla S. Clinical and biochemical outcome after hydroxocobalamin dose escalation in a series of patients with cobalamin C deficiency[J]. Mol Genet Metab, 2013, 109(4): 360-365.
[22] Pastore A, Martinelli D, Piemonte F. Glutathione metabolism in cobalamin deficiency type C (cblC)[J]. J Inherit Metab Dis, 2014, 37(1): 125-1299.